Global Gaucher Disease Treatment Market Analysis – Key Insights & Trends
Gaucher disease (GD) is a metabolic disorder that disrupts the recycling of cellular glycolipids, attributable to a deficiency in the lysosomal enzyme glucocerebrosidase (EC3.2.1.45), commonly referred to as glucosyl ceramidase or acid beta-glucosidase (GBA). In individuals diagnosed with GD, glucosylceramide, also known as glucocerebroside, along with several related compounds, accumulates within cell lysosomes due to impaired degradation processes that typically convert these substrates into glucose and lipid components.